PMID- 23870670
OWN - NLM
STAT- MEDLINE
DCOM- 20140313
LR  - 20131227
IS  - 1097-6825 (Electronic)
IS  - 0091-6749 (Linking)
VI  - 133
IP  - 1
DP  - 2014 Jan
TI  - Efficacy of a short course of specific immunotherapy in patients with allergic 
      rhinoconjunctivitis to ragweed pollen.
PG  - 121-9.e1-2
LID - S0091-6749(13)00907-X [pii]
LID - 10.1016/j.jaci.2013.05.032 [doi]
AB  - BACKGROUND: Specific immunotherapy acts to modify the underlying cause of 
      allergic rhinoconjunctivitis. Addition of adjuvants, such as monophosphoryl lipid 
      A (MPL), might allow for efficacious and safe treatment with only 4 injections 
      administered preseasonally, which is in contrast to most available schedules 
      requiring long injection courses. OBJECTIVE: The primary objective was to assess 
      the clinical efficacy of Ragweed MATA MPL (short ragweed pollen allergoid 
      adsorbed to L-Tyrosine + MPL) versus placebo in reducing allergic 
      rhinoconjunctivitis symptoms caused by ragweed pollen in an environmental 
      exposure chamber (EEC) 3 weeks after treatment. METHODS: This was a randomized, 
      double-blind, placebo-controlled phase IIb study to evaluate the clinical 
      efficacy and safety of Ragweed MATA MPL compared with placebo by using controlled 
      ragweed pollen exposure in an EEC. Two hundred twenty-eight patients with a 
      history of ragweed allergy and positive skin prick test responses to ragweed were 
      randomized and received 4 weekly injections of active treatment or placebo. Total 
      nasal and nonnasal symptom scores were obtained in the EEC before and after 
      treatment. RESULTS: Mean improvement in total symptom scores in the Ragweed MATA 
      MPL group was statistically significantly greater than in the placebo group 
      (relative mean improvement of active vs placebo, 48%; P < .05; median 
      improvement, 82%). The majority of adverse events (AEs) experienced by subjects 
      were mild injection-site reactions. No severe systemic AEs or serious AEs 
      occurred during the study. CONCLUSION: This study demonstrated that an ultrashort 
      course of Ragweed MATA MPL is efficacious in reducing allergy symptoms in 
      patients with seasonal allergic rhinitis and that it is well tolerated.
CI  - Copyright (c) 2013 American Academy of Allergy, Asthma & Immunology. Published by 
      Mosby, Inc. All rights reserved.
FAU - Patel, Piyush
AU  - Patel P
AD  - Allied Research International, Mississauga, Ontario, Canada. Electronic address: 
      PPatel@inflamaxresearch.com.
FAU - Holdich, Tom
AU  - Holdich T
AD  - Allergy Therapeutics, West Sussex, United Kingdom.
FAU - Fischer von Weikersthal-Drachenberg, Karl J
AU  - Fischer von Weikersthal-Drachenberg KJ
AD  - Bencard Allergie, Munich, Germany.
FAU - Huber, Birgit
AU  - Huber B
AD  - Bencard Allergie, Munich, Germany.
LA  - eng
PT  - Clinical Trial, Phase II
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20130716
PL  - United States
TA  - J Allergy Clin Immunol
JT  - The Journal of allergy and clinical immunology
JID - 1275002
RN  - 0 (Allergens)
RN  - 0 (Antigens, Plant)
RN  - 0 (Lipid A)
RN  - 0 (Plant Extracts)
RN  - 0 (ragweed MATA MPL)
RN  - 0 (ragweed pollen)
RN  - Ragweed Sensitivity
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Allergens/adverse effects/immunology
MH  - Ambrosia/*immunology
MH  - Antigens, Plant/*adverse effects
MH  - Clinical Protocols
MH  - Conjunctivitis, Allergic/*therapy
MH  - Desensitization, Immunologic/*methods
MH  - Environmental Exposure/adverse effects
MH  - Female
MH  - Humans
MH  - Hypersensitivity, Immediate/*therapy
MH  - Lipid A/*analogs & derivatives/therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Plant Extracts/*adverse effects/*therapeutic use
MH  - Rhinitis, Allergic, Seasonal/*therapy
MH  - Treatment Outcome
MH  - Young Adult
OTO - NOTNLM
OT  - AE
OT  - AR
OT  - Adverse event
OT  - Allergic rhinoconjunctivitis
OT  - EEC
OT  - Environmental exposure chamber
OT  - ITT
OT  - Intention to treat
OT  - MPL
OT  - Monophosphoryl lipid A
OT  - PP
OT  - Per protocol
OT  - RQLQ
OT  - Rhinoconjunctivitis Quality of Life Questionnaire
OT  - SAR
OT  - SIT
OT  - SU
OT  - Seasonal allergic rhinitis
OT  - Specific immunotherapy
OT  - Standardized units
OT  - TSS
OT  - Total symptom score
OT  - environmental exposure chamber
OT  - ragweed
OT  - specific immunotherapy
OT  - ultrashort course
EDAT- 2013/07/23 06:00
MHDA- 2014/03/14 06:00
CRDT- 2013/07/23 06:00
PHST- 2012/10/11 00:00 [received]
PHST- 2013/04/19 00:00 [revised]
PHST- 2013/05/22 00:00 [accepted]
PHST- 2013/07/23 06:00 [entrez]
PHST- 2013/07/23 06:00 [pubmed]
PHST- 2014/03/14 06:00 [medline]
AID - S0091-6749(13)00907-X [pii]
AID - 10.1016/j.jaci.2013.05.032 [doi]
PST - ppublish
SO  - J Allergy Clin Immunol. 2014 Jan;133(1):121-9.e1-2. doi: 
      10.1016/j.jaci.2013.05.032. Epub 2013 Jul 16.